← Leaderboards
David E Kaplan
Philadelphia Va Medical Center
$1,835,304
Attributed
$2,056,093
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $441.6K · FY2010–25$500K$375K$250K$125K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,056,093 · 3
VA$0 · 4
By mechanism
R01$1,759,618 · 2
R21$296,475 · 1
I01$0 · 4
Top collaborators
- Tamar Taddei5 shared
- Terence P Gade2 shared
- David Seth Goldberg1 shared
Most similar at Philadelphia Va Medical Center
Same institution · by research overlap
- Amy Caroline Justice$51,314,210
- Tamar Taddei$0
Others in their field
Top investigators on “Cessation Of Life”
- David R. Weir · University Of Michigan At Ann Arbor$345,522,974
- John M Lachin · George Washington University$134,302,892
- David M Nathan · Massachusetts Institute Of Technology$127,791,564
- Judith S Hochman · New York University School Of Medicine$112,898,313
- Jeffrey H Samet · Boston University Medical Campus$91,739,367
- Judith S. Currier · University Of California Los Angeles$85,330,415
Research focus
Cessation Of LifePrimary Carcinoma Of The Liver CellsLiver TransplantationInfectionCirrhosisCellsLiverHepatitis CIn VivoVeteransIn VitroMediatingImmuneIncidencePreventBaseChronicProspectivePortal HypertensionProspective StudiesVirus DiseasesHepatitis C VirusHepatitis B VirusLiver Fibrosis
Grant awards (21)
The role of immunosuppression and environmental exposures on incident and subsequent keratinocyte carcinoma risk after solid organ transplant$441,578
R01 · FY2025 · CA · contact PI
Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis$0
I01 · FY2025 · VA · contact PI
Targeting Ischemia-Induced Autophagy Dependence in hepatocellular Carcinoma through Image-guided Locoregional Therapy$0
I01 · FY2024 · VA
Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis$0
I01 · FY2024 · VA · contact PI
Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis$0
I01 · FY2023 · VA · contact PI
Targeting Ischemia-Induced Autophagy Dependence in hepatocellular Carcinoma through Image-guided Locoregional Therapy$0
I01 · FY2023 · VA
Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis$0
I01 · FY2022 · VA · contact PI
Cross-comparison of patient-derived xenografts and derivative organoids and cell lines for translational research in hepatocellular carcinoma$0
I01 · FY2021 · VA · contact PI
Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis$0
I01 · FY2020 · VA · contact PI
Cross-comparison of patient-derived xenografts and derivative organoids and cell lines for translational research in hepatocellular carcinoma$0
I01 · FY2020 · VA · contact PI
B-Cell Dysregulation in Cirrhosis due to Chronic Hepatitis C Infection$0
I01 · FY2019 · VA · contact PI
B-Cell Dysregulation in Cirrhosis due to Chronic Hepatitis C Infection$0
I01 · FY2017 · VA · contact PI
Tumor antigen-specific T-cells and hepatocellular carcinoma$332,000
R01 · FY2016 · CA · contact PI
B-Cell Dysregulation in Cirrhosis due to Chronic Hepatitis C Infection$0
I01 · FY2016 · VA · contact PI
Tumor antigen-specific T-cells and hepatocellular carcinoma$332,000
R01 · FY2015 · CA · contact PI
B-Cell Dysregulation in Cirrhosis due to Chronic Hepatitis C Infection$0
I01 · FY2015 · VA · contact PI
Tumor antigen-specific T-cells and hepatocellular carcinoma$322,040
R01 · FY2014 · CA · contact PI
B-Cell Dysregulation in Cirrhosis due to Chronic Hepatitis C Infection$0
I01 · FY2014 · VA · contact PI
Tumor antigen-specific T-cells and hepatocellular carcinoma$332,000
R01 · FY2013 · CA · contact PI
Engineered lymphocytes for the treatment of hepatocellular carcinoma$159,497
R21 · FY2011 · CA · contact PI
Engineered lymphocytes for the treatment of hepatocellular carcinoma$136,978
R21 · FY2010 · CA · contact PI